Edgewise Therapeutics (EWTX) is up 16.5% today. Here is some analysis on what might have caused this price movement.
Analysis: A single fresh catalyst is not obvious, but the move appears tied to continued investor enthusiasm around Edgewise’s post-transaction profile after completing the sale of sevasemten and its muscular dystrophy business. This could also be because traders are refocusing on the company’s strengthened balance sheet, its sharpened cardiovascular strategy, and an earnings report expected this week.
Details:
Edgewise said on July 13 that it completed the sale of sevasemten and related muscular dystrophy assets for $1.55 billion upfront, with up to $1.1 billion more tied to milestones, leaving the company centered on cardiovascular programs.The company said those upfront proceeds are expected to fund development of EDG-7500 through potential approval, which reduces financing pressure that often weighs on clinical-stage biotech stocks.Edgewise also highlighted positive 12-week Phase 2 data for EDG-7500 in hypertrophic cardiomyopathy and said it expects to start a Phase 3 trial in the fourth quarter of 2026.Market calendars show Edgewise is scheduled to report earnings on August 6, 2026, which may be contributing to positioning ahead of a corporate update.Sources:
Edgewise Therapeutics, SEC, TipRanks
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$EWTX Insider Trading Activity
$EWTX insiders have traded $EWTX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $EWTX stock by insiders over the last 6 months:
- ALAN J RUSSELL (Chief Scientific Officer) has made 0 purchases and 2 sales selling 200,000 shares for an estimated $7,881,401.
- JOANNE M. DONOVAN (CMO) has made 0 purchases and 6 sales selling 121,588 shares for an estimated $4,210,201.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Quiver Alerts
Receive EWTX Data Alerts
Get market-moving data, filings, and signals for EWTX in real time.
Sign Up
$EWTX Hedge Fund Activity
We have seen 90 institutional investors add shares of $EWTX stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARADIGM BIOCAPITAL ADVISORS LP added 823,828 shares (+12.6%) to their portfolio in Q1 2026, for an estimated $25,950,582
- UBS GROUP AG removed 805,948 shares (-38.1%) from their portfolio in Q1 2026, for an estimated $25,387,362
- ALLIANCEBERNSTEIN L.P. added 685,999 shares (+66.2%) to their portfolio in Q1 2026, for an estimated $21,608,968
- MORGAN STANLEY removed 664,853 shares (-22.8%) from their portfolio in Q1 2026, for an estimated $20,942,869
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 571,855 shares (-36.3%) from their portfolio in Q1 2026, for an estimated $18,013,432
- SOLEUS CAPITAL MANAGEMENT, L.P. added 539,915 shares (+59.3%) to their portfolio in Q1 2026, for an estimated $17,007,322
- QUBE RESEARCH & TECHNOLOGIES LTD added 529,702 shares (+178.8%) to their portfolio in Q1 2026, for an estimated $16,685,613
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$EWTX Price Targets
Multiple analysts have issued price targets for $EWTX recently. We have seen 8 analysts offer price targets for $EWTX in the last 6 months, with a median target of $48.0.
Here are some recent targets:
- Mazahir Alimohamed from Oppenheimer set a target price of $51.0 on 07/09/2026
- Debjit Chattopadhyay from Guggenheim set a target price of $51.0 on 07/06/2026
- Paul Choi from Goldman Sachs set a target price of $32.0 on 06/17/2026
- Leonid Timashev from RBC Capital set a target price of $59.0 on 06/17/2026
- Lander Egaña Gorroño from HC Wainwright & Co. set a target price of $45.0 on 06/16/2026
- Laura Chico from Wedbush set a target price of $52.0 on 06/02/2026
- Tessa Romero from JP Morgan set a target price of $45.0 on 03/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »
View the Zacks #1 Rank List
Edgewise Therapeutics gains as investors weigh cash-rich reset and cardiovascular pipeline progress
Edgewise Therapeutics (EWTX) is up 16.5% today. Here is some analysis on what might have caused this price movement.
Analysis: A single fresh catalyst is not obvious, but the move appears tied to continued investor enthusiasm around Edgewise’s post-transaction profile after completing the sale of sevasemten and its muscular dystrophy business. This could also be because traders are refocusing on the company’s strengthened balance sheet, its sharpened cardiovascular strategy, and an earnings report expected this week.
Details:
Sources:
Edgewise Therapeutics, SEC, TipRanks
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$EWTX Insider Trading Activity
$EWTX insiders have traded $EWTX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $EWTX stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$EWTX Hedge Fund Activity
We have seen 90 institutional investors add shares of $EWTX stock to their portfolio, and 83 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$EWTX Price Targets
Multiple analysts have issued price targets for $EWTX recently. We have seen 8 analysts offer price targets for $EWTX in the last 6 months, with a median target of $48.0.
Here are some recent targets:
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Read full article here »